Skip to main content
. 2020 Aug 11;2020(8):CD008016. doi: 10.1002/14651858.CD008016.pub3

NCT03893825.

Study name A study to test if TV‐46000 is safe for maintenance treatment of schizophrenia
Methods Randomised controlled trial.
Participants Schizophrenia, in maintenance/relapse prevention phase.
Interventions TV‐46000 (risperidone extended release injectable suspension) versus matching placebo.
Outcomes Number of adverse events, dropouts due to adverse events.
Starting date April 2019
Contact information USMedInfo@tevapharm.com
Notes